GlassScriptPhysician profile
Shirlann D Knight
NPI 1982810198
$11,371.61
in general payments reported to CMS, 2019-2025
21 companies · $3,669 in 2025
The $3,669 reported for 2025 was more than what 94% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,076 · 2020: $1,301 · 2021: $568 · 2024: $3,757 · 2025: $3,669.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,352 · Education: $74.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,351.60 |
| Education | $74.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,804.04 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $1,504.48 | 2019-2025 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $1,177.22 | 2019-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Teva Pharmaceuticals USA, INC. | $1,162.09 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Alkermes, INC. | $885.59 | 2019-2025 | Aristada, Lybalvi |
| Allergan, INC. | $818.22 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $794.29 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $735.27 | 2024-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $675.36 | 2019-2025 | Ingrezza |
| Lundbeck LLC | $439.70 | 2019-2025 | Rexulti, Abilify Maintena |
| Abbvie INC. | $354.12 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $352.13 | 2020-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $348.58 | 2019-2021 | |
| Indivior INC. | $90.83 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $69.53 | 2019-2024 | Trintellix |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $50.49 | 2019 | |
| Shire North American Group INC | $38.74 | 2019 | |
| Tempus Ai, INC | $33.55 | 2024 | |
| Ironshore Pharmaceuticals INC. | $14.17 | 2024 | |
| Merck Sharp & Dohme LLC | $12.45 | 2019 | |
| Neuronetics, INC. | $10.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shirlann Knight listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.